Medication info
Telmitri One 40/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Telmitri One 40/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Ilseong IS Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500660 · Approved 2025.03.24 · Insurance code 655404810

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking the telmisartan/amlodipine combination together with rosuvastatin alone may switch to this medicine (a combination containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination It is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan) before administering the telmisartan/amlodipine combination. However, if blood pressure is not controlled with the individual components as follows, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this medicine 40/10 milligrams. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan in patients with mild or moderate hepatic impairment should not exceed 40 milligrams. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin, whether before or during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. A maintenance dose of 10 milligrams once daily controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment target, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Since systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram rosuvastatin dose is contraindicated in some of these patients.

Ingredients

Manufacturer
Ilseong IS Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of premature coronary artery disease.
View approved original text

This medication is used in patients with essential hypertension who have not adequately controlled blood pressure with telmisartan and amlodipine alone. Additionally, rosuvastatin serves as an adjunct to diet for patients with hypercholesterolemia and mixed dyslipidemia to lower cholesterol levels and slow the progression of atherosclerosis. It is also beneficial for patients with familial hypercholesterolemia or dysbetalipoproteinemia. Furthermore, this drug reduces the risk of cardiovascular diseases, particularly stroke, myocardial infarction, and the recurrence risk after arterial revascularization. Therefore, this medication effectively improves the condition of patients with both hypertension and hyperlipidemia.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking the telmisartan/amlodipine combination together with rosuvastatin alone may switch to this medicine (a combination containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination It is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan) before administering the telmisartan/amlodipine combination. However, if blood pressure is not controlled with the individual components as follows, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this medicine 40/10 milligrams. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan in patients with mild or moderate hepatic impairment should not exceed 40 milligrams. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin, whether before or during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. A maintenance dose of 10 milligrams once daily controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment target, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Since systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram rosuvastatin dose is contraindicated in some of these patients.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy, thus it must be discontinued immediately upon confirmation of pregnancy. Additionally, women of childbearing potential should use appropriate contraceptive measures, and breastfeeding women should avoid taking this medication. Patients with allergies to any of the components of this drug or specific liver or kidney diseases should not take it. Particularly, patients with severe liver dysfunction or kidney dysfunction should also avoid administration. Caution is required when administering to the elderly, patients with hypotension, or those with hyperkalemia, and regular liver function tests or muscle-related exams should be conducted. If symptoms such as muscle pain or weakness occur, consultation with a doctor should be sought immediately, and drug use may be discontinued in severe cases. This medication may interact with other drugs, and if the patient is taking other medications, they must inform their doctor or pharmacist. In case of overdose, symptoms such as hypotension, dizziness, and cardiac arrhythmias may occur, and appropriate medical treatment should be sought immediately. This medication is not recommended for children as its safety and efficacy have not been sufficiently established.

Side effects

Viral upper respiratory tract infection, dyspnea, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, hiatal hernia, sensory impairment, movement disorder, dysuria, rhinitis, oropharyngeal discomfort, lung disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, lumbago, sinusitis, diarrhea, pharyngitis, influenza-like syndrome, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, cough, hypertension, chest pain, nausea, erectile dysfunction, erectile dysfunction, autonomic nervous system disorder, fever, leg pain, malaise, palpitations, dependent edema, angina pectoris, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, vertigo, sensory abnormality, involuntary muscle contractions, flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal disease, gout, hypercholesterolemia, diabetes, arthritis, arthralgia, leg numbness, anxiety, depression, nervous irritability, infection, fungal infection, abscess, otitis media, asthma, bronchitis, rhinitis, epistaxis, dermatitis, rash, eczema, pruritus, angioedema, erythema multiforme, papular rash, frequent urination, cystitis, cerebrovascular disease, visual disturbances, conjunctivitis, ear pain, angioedema, headache, edema, dizziness, flushing, palpitations, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, orthostatic hypotension, vasculitis, peripheral neuropathy, tremors, appetite loss, dysphagia, pancreatitis, gingival hyperplasia, allergic reaction, burning sensation, malaise, rigidity, weight gain, weight loss, degenerative joint disease, muscle cramps, sexual dysfunction, insomnia, abnormal dreams, depersonalization, eosinophilia, thrombocytopenia, leukopenia, purpura, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, myasthenia, increased CK, myalgia, myopathy, rhabdomyolysis, acute renal failure, hypotension, tachycardia, bradycardia, dizziness, acute renal failure, excessive peripheral vasodilation, reflex tachycardia, systemic hypotension, non-cardiogenic pulmonary edema, headache, dizziness, myasthenia, cough, nausea, fatigue, weakness, edema, facial edema, limb edema, angioedema, pruritus, hypersensitivity reaction, increased sweating, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, elevated blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, dyspepsia, lumbago, abdominal pain, muscle cramps, myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, liver function abnormalities, liver disease, anemia, elevated CPK, anaphylactic reaction, tendon pain, rhabdomyolysis, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, DRESS, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, memory impairment, forgetfulness, amnesia, memory disorder, confusion, myasthenia gravis.

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be kept in a tightly closed container that protects it from light, and it is recommended to store it at room temperature between 1 and 30 degrees Celsius. Storing it this way will maintain its effectiveness and safety.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.